Article
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Cell - 20 Sept 2018
Huang Xun, Yan Juan, Zhang Min, Wang Yafang, Chen Yi, Fu Xuhong, Wei Rongrui, Zheng Xing-Ling, Liu Zhiwei, Zhang Xiong, Yang Hong, Hao Bingbing, Shen Yan-Yan, Su Yi, Cong Xiaoji, Huang Min, Tan Minjia, Ding Jian, Geng Meiyu
Abstract excerpt
Mutations or aberrant upregulation of EZH2 occur frequently in human cancers, yet clinical benefits of EZH2 inhibitor (EZH2i) remain unsatisfactory and limited to certain hematological malignancies. We profile global posttranslational histone modification changes across a large panel of cancer cell lines with various sensitivities to EZH2i. We report here oncogenic transcriptional reprogramming mediated by MLL1's...
Topics
- Animals
- Carcinogenesis
- Cell Cycle Proteins
- Cell Line, Tumor
- Enhancer of Zeste Homolog 2 Protein
- Epigenesis, Genetic
- Epigenomics
- Female
- Gene Expression Regulation, Neoplastic
- Histone Code